Antibiotic resistance is the third leading cause of death, globally, claiming almost 5 million lives every year, with this projected to increase …
An Unlicensed Distribution Agreement with Inceptua allows Pharmaceutical companies to make their approved medicines available in countries where they are not yet approved or commercially available.
Pharmaceutical companies can decide to make their products available through named patient pathways, typically on a for-charge basis and after they have obtained regulatory approval in at least one country. This is later in the lifecycle compared to Early Access Programs, which can start as early as clinical Phase II or Phase III.
Demand for access may exist globally outside of the core launch markets, so named patient pathways can be used to provide open-ended access through one single partner.
Usually on an exclusive basis per territory, Inceptua can be your single, trusted partner for the reliable and compliant provision of medicines into territories where the medicines has not yet launched, or in countries and regions where the medicine will never be commercially available.
Why Inceptua:
1. Access to markets allowing Pharma companies to sell their products in (120 + territories) and 1000’s of potential customers globally
2. Experts in establishing pricing strategies for an unlicensed medicine aligned to a company’s global pricing and market access approach
3. Support patients and physicians in finding reimbursement for an unlicensed medicine in a specific country, where funding is available
4. Compliant strategies and tactics to build awareness of your program
Ask our experts
Antibiotic resistance is the third leading cause of death, globally, claiming almost 5 million lives every year, with this projected to increase …
Antibiotic resistance is the third leading cause of death, globally, claiming almost 5 million lives every year, with this projected to increase …
Antibiotic resistance is the third leading cause of death, globally, claiming almost 5 million lives every year, with this projected to increase …
